Rhythm Pharmaceuticals, Inc. RYTM Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$55.64M-12.4% | -$47.51M-9.7% | -$52.9M-21.1% | -$46.63M-44.5% | -$49.5M+65.0% | ||
| $23.1M+79.6% | $19.27M+82.5% | $18.81M+71.0% | $15.88M+53.3% | $12.86M+65.6% | ||
| $8.11M+1,280% | —— | $6.6M+286% | $7.83M+170% | -$687K-299% | ||
| $3.09M+437% | $4.93M+1.7% | $2.45M+28.9% | $0-100% | $575K+591% | ||
| -$5.62M-54.6% | $1.26M-91.7% | $11.02M+46.7% | $13.26M+2,650% | -$3.63M-190% | ||
| -$435K-326% | $681K+114% | $5.24M+677% | -$5.42M-415% | -$102K+91.5% | ||
| -$178K— | —— | —— | —— | $0— | ||
| -$145K+88.7% | —— | —— | —— | -$1.29M— | ||
| -$44.19M-9.5% | -$25.39M-34.7% | -$26.62M-5.6% | -$23.31M+19.8% | -$40.35M+1.0% | ||
| $42.2M+25.9% | $20.35M-69.3% | $267.85M+97.5% | $26.95M— | $33.52M— | ||
| $99.25M+70.1% | $51.65M-41.0% | $61.5M+35.7% | $80.99M+40.2% | $58.33M-16.7% | ||
| $57.05M+130% | —— | -$246.35M-171% | $54.04M— | $24.81M-17.4% | ||
| $4.29M-7.1% | $5.4M+41.8% | $5.57M+67.0% | $4.33M+45.7% | $4.62M+65.8% | ||
| $0-100% | $22.88M-12.5% | —— | —— | $34.03M+436% | ||
| $8.46M— | —— | —— | —— | $0— | ||
| -$5.4M-117% | —— | $189.3M+7,496% | —— | $32.5M+666% | ||
| $448K+22,500% | $64K-93.4% | $304K+150% | -$279K+7.3% | -$2K+97.2% | ||
| $7.92M-53.3% | $0-100% | -$83.36M+27.0% | $29.55M-72.7% | $16.96M+360% | ||
| $113K+2.7% | $109K-1.8% | $104K-3.7% | $105K+50.0% | $110K-0.9% | ||
| $252K-34.2% | $272K-29.0% | $304K-21.0% | $379K-2.8% | $383K-5.4% | ||
| -$1.35M— | —— | —— | $1.71M— | $0— | ||
| -$145K+88.7% | —— | —— | —— | -$1.29M— | ||
| $330K+313% | -$130K-8.3% | -$360K+29.4% | -$500K-66.7% | $80K+116% | ||
| $487K-84.8% | $2.71M-52.6% | —— | $6.8M+351% | $3.2M+32.3% | ||
| -$1.44M+19.6% | -$1.86M+13.2% | -$1.7M+31.2% | -$1.18M+46.2% | -$1.79M-30.4% | ||
| $4.58M-15.4% | $4.62M-15.3% | $4.74M-9.5% | $5.82M-1.5% | $5.41M+34.9% | ||
| -$178K— | —— | —— | —— | $0— | ||
| $42.2M+25.9% | $20.35M-69.3% | $267.85M+97.5% | $26.95M— | $33.52M— | ||
| $99.25M+70.1% | $51.65M-41.0% | $61.5M+35.7% | $80.99M+40.2% | $58.33M-16.7% | ||
| —— | $47.16M— | $47.16M— | $47.16M— | $47.16M— | ||
| $1.25M+46.5% | $1K— | $729K+22.1% | $0— | $854K+26.9% | ||
| $448K+22,500% | $64K-93.4% | $304K+150% | -$279K+7.3% | -$2K+97.2% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $1.1M-16.5% | $1.33M-0.5% | $1.38M+3.5% | $1.35M+3.6% | $1.32M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Rhythm Pharmaceuticals, Inc. generate?
- Rhythm Pharmaceuticals, Inc. (RYTM) generated -$119.5M in operating cash flow over the trailing twelve months.
- Where does Rhythm Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Rhythm Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
